Delivering innovative solutions to drive growth and impact

“I’m extremely proud of the BD team for their execution this quarter, as we delivered sequential improvement across each of our segments and successfully launched our BD Veritor™ SARS-CoV-2 assay. Collectively, we drove mid-single-digit revenue growth, building on the strength of our COVID-19 diagnostics revenues to overcome headwinds from both COVID-19 and Alaris. Looking to fiscal 2021, BD remains focused on partnering with governments, health care systems, and health care professionals to navigate the COVID-19 pandemic, ensure access to rapid diagnostics and enable care for patients around the world. We are aligned on our priorities and steadfast in our commitments, including completing our Alaris 510(k) submission, investing in innovation and strategic growth initiatives, simplifying our processes and empowering our organization.”

—Tom Polen, CEO and President

Delivering innovation to expand testing capabilities essential for rapid COVID-19 detection

BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2

Doubling BD Veritor™ readers to

>50,000

Supporting

12,000+

U.S. nursing homes

>10M units shipped

Commitments for over

800M injection devices

Leveraging our global scale and manufacturing excellence for vaccination campaign readiness

Supporting global and local communities by donating

$23.2M in product and cash through BD and the BD Foundation

Q4 FY20

Revenue growth of 4.4% on a year-over-year basis

Adjusted EPS of $2.79

1. Reflects the number of BD Veritor™ active readers since the launch of the SARS-CoV-2 assay.
2. For the twelve-month period ended September 30, 2020.
3. As of November 2020.
5. Reflects currency revenue growth for the three-month period ended September 30, 2020 compared to the comparable period in 2019 on a year-over-year basis.
6. Reflects adjusted non-GAAP earnings per share, which excludes, among other things, the impact of purchase accounting adjustments (including the write-off of acquisition-related intangible assets), integration, restructuring and transaction costs.

These materials include non-GAAP financial measures. A reconciliation to the comparable GAAP measures can be found in our financial schedules and on the “Investors” section of the BD.com website.

This document contains forward-looking statements and it’s possible that actual results could differ from our expectations. Factors that could cause such differences appear in our fiscal Q4 2020 earnings release furnished as an exhibit to the Form 8-K that BD filed on November 5, 2020 with the SEC, and in our annual SEC filings.